{"filing":{"accession_number":"0001213900-26-111794","cik":"0002002988","ticker":null,"company_name":"Retension Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-10-22","report_date":"2026-10-21","primary_document":"ea0309450-8k_retension.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2002988/000121390026111794/ea0309450-8k_retension.htm"},"events":[{"id":37371,"run_id":34449,"accession_number":"0001213900-26-111794","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"The filing discloses the appointment of Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Officer) of Retension Pharmaceuticals, effective November 2, 2026. The principal disclosed action is a person taking a role—a key executive position responsible for accounting and financial reporting. While the filing also includes compensatory details (base salary, bonus, sign-on bonus, and stock options), the core event is the appointment itself, making this an exec_appointment rather than exec_compensation.","company_name":"Retension Pharmaceuticals, Inc.","ticker":null,"filing_date":"2026-10-22","form":"8-K","submitted_at":null,"items":[{"id":42063,"accession_number":"0001213900-26-111794","item_number":"5.02","item_title":"Departure of Directors or","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Officer) of Retension Pharmaceuticals, effective November 2, 2026. The principal disclosed action is a person taking a role—a key executive position responsible for accounting and financial reporting. While the filing also includes compensatory details (base salary, bonus, sign-on bonus, and stock options), the core event is the appointment itself, making this an exec_appointment rather than exec_compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:02:10.043793+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42063,"accession_number":"0001213900-26-111794","item_number":"5.02","item_title":"Departure of Directors or","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Robert Wong as Vice President, Chief Accounting Officer (Principal Accounting Officer) of Retension Pharmaceuticals, effective November 2, 2026. The principal disclosed action is a person taking a role—a key executive position responsible for accounting and financial reporting. While the filing also includes compensatory details (base salary, bonus, sign-on bonus, and stock options), the core event is the appointment itself, making this an exec_appointment rather than exec_compensation.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T10:02:10.043793+00:00","company_name":"Retension Pharmaceuticals, Inc.","ticker":null,"filing_date":"2026-10-22"}]}